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Previous research has demonstrated that, in male rats,
the magnitude of contact hypersensitivity (CHS) can
be enhanced by morphine treatment. The present ex-
periments test the hypothesis that the l-opioids mor-
phine, etorphine, and buprenorphine would produce
signi¢cant sex di¡erences in the magnitude of 2,4-
dinitro£uorobenzene-induced CHS. During tests con-
ducted over a 192-h period, morphine, etorphine, and
buprenorphine administered before elicitation of CHS
on the external surface of the ear (pinna) potentiated
the CHS response, and the magnitude of this enhance-
ment was signi¢cantly greater in females than males.
By contrast, morphine had no e¡ect on croton oil-
induced irritant contact dermatitis, indicating that
morphine’s e¡ects on CHS do not generalize to
immunologically nonspeci¢c forms of contact dermati-
tis. Activation of brain l-opioid receptors is responsible
for the e¡ects of morphine on CHS, because intracere-
broventricular treatment with the l-opioid receptor
antagonist b-funaltrexamine blocked morphine poten-
tiation of CHS in females and males.The sex di¡erences
in morphine potentiation of CHS appear to be a result
of the gonadal hormonal milieu, because castration en-
hanced the CHS response following vehicle and mor-
phine treatment, whereas ovariectomy signi¢cantly
attenuated the enhancement of CHS by morphine.
Because ovariectomy had no e¡ect on the CHS
response following vehicle treatment, the presence of
female gonadal hormones may underlie the sex di¡er-
ences in morphine potentiation of CHS in gonadally
intact animals. Overall, these results support an in-
creased sensitivity to the modulatory e¡ects of opioids
on the CHS response in females that depends on the inter-
action between gonadal hormones and the central
l-opioid system. Key words: contact dermatitis/morphine/etor-
phine/buprenorphine. J Invest Dermatol 121:1053 ^1059, 2003
C
ontact hypersensitivity (CHS) is a cutaneous form
of delayed-type hypersensitivity that results in in-
£ammation following multiple exposures to a hap-
tenized chemical antigen. This prevalent condition
accounts for 20% to 25% of all cases of contact der-
matitis (Marks, 2002). Following initial exposure to the hapten
(sensitization), proin£ammatory cytokines such as interleukin-1b
and tumor necrosis factor-a are rapidly produced (Enk and Katz,
1992) that activate Langerhans cells and stimulate antigen proces-
sing. In addition, these cytokines promote Langerhans cell migra-
tion to the skin-draining lymph nodes, where they present
antigen to na|«ve T cells that di¡erentiate into antigen-speci¢c
memoryTcells (for a review see Grabbe and Schwarz, 1998). After
subsequent exposure to the antigen (elicitation), a host of proin-
£ammatory cytokines and chemokines are produced by local ker-
atinocytes and monocytes at the elicitation site along with
upregulation of major histocompatibility complex and adhesion
molecules resulting in in¢ltration of other cells such as neutro-
phils and T lymphocytes (Grabbe and Schwarz, 1998). Like other
delayed-type hypersensitivity responses, CHS has been classically
viewed asTh1-mediated (Cher and Mosmann, 1987); however, re-
cent evidence suggests the key involvement of both Th2 and
CD8þ cells (Bour et al, 1995; Xu et al, 1996). Therefore, CHS is
an immunologically complex, oligoclonal response to epicuta-
neously applied haptens that results in swelling, redness, and pain
at the elicitation site.
Recent studies indicate that the magnitude of the CHS
response can be dramatically altered in rodents by pharmacologic
manipulations. Work in our laboratory has demonstrated that
morphine given before elicitation of CHS (but not sensitization
with antigen) signi¢cantly increases pinna swelling in a model of
2,4 -dinitro£uorobenzene (DNFB)-induced CHS in male rats
(Nelson et al, 1999). Follow-up work demonstrated the involve-
ment of proin£ammatory mediators, brain opioid receptors, and
neurokinin-1 receptor activation in the ear in mediating the ef-
fects of morphine on the CHS response (Nelson and Lysle,
2001a, b). In addition to enhancing the CHS response, morphine
has many other immunomodulatory e¡ects including degranulat-
ing cutaneous mast cells (Marone et al, 1993; Di Bello et al, 1998),
altering T and B lymphocyte proliferation (Lysle et al, 1993), and
increasing nitric oxide production (Fecho et al, 1994). Taken to-
gether, these results demonstrate that morphine is an immuno-
modulatory drug that acts via central opioid receptors to
potentiate CHS in male rats by increasing levels of various proin-
£ammatory mediators at the site of CHS elicitation.
To date, the investigations of the e¡ects of morphine on the
CHS response have focused on male animals. Given identi¢ed
sex di¡erences in opioid-induced antinociception (Cicero et al,
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1996; Cook et al, 2000; Sarton et al, 2000), physical dependence
(Cicero et al, 2002), and emesis (Zun et al, 2002), sex is likely to
be a crucial determinant of the magnitude of opioid modulation
of CHS. Furthermore, there is evidence suggesting that gonadal
hormones may mediate these sex di¡erences because gonadect-
omy has been shown to attenuate or reverse observed sex di¡er-
ences in opioid antinociception (Terner et al, 2002). Therefore,
this investigation tested the hypotheses that morphine and other
m-opioids will produce sex di¡erences in the CHS response
and that these sex di¡erences will depend on gonadal hormone
milieu.
In these experiments, the e¡ect of several selective m-opioids
on the magnitude of DNFB-induced CHS was assessed in male
and female rats.To that end, animals were administered vehicle or
selected doses of the m-opioids morphine, etorphine, or bupre-
norphine before CHS elicitation with DNFB. Morphine and bu-
prenorphine are clinically used analgesics with high and low
e⁄cacy at the m receptor, respectively, whereas etorphine is a rela-
tively short-acting high-e⁄cacy agonist at the m-opioid receptor.
Buprenorphine (Subutex, Schering-Plough Corp., Kenilworth,
NJ) has also recently been approved by the US Food and Drug
Administration as a treatment for heroin dependence that can be
prescribed by primary care physicians. These drugs were chosen
to test the generalizability of observed sex di¡erences to a range
of clinically used opioids and establish the immunomodulatory
e¡ects of buprenorphine and etorphine in the skin. Subsequently,
experiments were conducted to assess potential mechanisms un-
derlying the observed e¡ects, including whether: (1) morphine’s
enhancement of the CHS response generalizes to the immunolo-
gically nonspeci¢c cutaneous in£ammatory response irritant con-
tact dermatitis (ICD); (2) morphine’s potentiation of the CHS
response in both males and females depends on activation of
brain and/or peripheral m-opioid receptors; and (3) sex di¡erences
in the e¡ects of morphine on the CHS response depends on the
gonadal hormone milieu.
MATERIALS AND METHODS
Animals Pathogen-free adult Fischer rats (3^6 mo of age) obtained from
Charles River (Raleigh, NC) were used in these investigations. Animals
were individually housed and kept on a 12:12-h light cycle with lights o¡
at 3 p.m. A combination of drug-na|«ve animals and animals who had
previously received brief exposure to opioids were used in the
concentration^response studies. All animals previously exposed to opioids
were given a drug-free period of at least 3 wk before receiving any
treatment in the present experiments. Fischer rats gonadectomized by the
vendor (Charles River) at approximately 60 d old were also used following
a 4-wk period after surgery to dissipate remaining circulating gonadal
hormones (Cicero et al, 1996). Postmortem examinations of gona-
dectomized animals were also conducted to con¢rm the absence of
ovaries or testes. All procedures employed in these studies were approved
by the Institutional Animal Care and Use Committee (IACUC) of the
University of North Carolina at Chapel Hill.
Drugs Morphine sulfate, etorphine hydrochloride, buprenorphine
hydrochloride, and b-funaltrexamine hydrochloride were provided by the
National Institute on Drug Abuse (NIDA, Bethesda, MD). All drugs,
except where noted, were dissolved in endotoxin-free sterile water and
delivered by subcutaneous injection to a site on the lateral lower abdomen
in a ¢nal volume of 1 mL per kg.
Induction of CHS Sensitization and elicitation of CHS with DNFB
(Sigma, St. Louis, MO) was performed as previously described (Nelson
et al, 1999). Brie£y, animals were sensitized with 100 mL of 1% DNFB (in
a 4:1 mixture of acetone and olive oil) applied to the shaved abdomen on
days 1 and 2 of the experiment. On day 6, the animals were administered
selected doses of morphine (2.5, 7.5, or 15 mg/kg), buprenorphine (0.01, 0.1,
or 1.0 mg/kg), etorphine (0.001, 0.005, or 0.01 mg/kg), or vehicle alone
(sterile water) by subcutaneous injection. One hour later, 25 mL of a 0.5%
DNFB solution was applied to the treatment ear (right pinna) to elicit the
CHS response. As a control, an equivalent volume of vehicle alone was
applied to the opposing ear (left pinna). The course of the in£ammatory
response was measured at 12 and 24 h after CHS elicitation and every
24 h thereafter to 192 h after elicitation.
Induction of ICD Induction of ICD was performed as previously
described (Nelson et al, 1999). Animals were treated with 15 mg per kg
morphine or equivalent volume of sterile water 1 h before elicitation of
ICD on the right pinna by the application of 50 mL of 10% croton oil
(Sigma) in a 4:1 acetone and olive oil vehicle. As a control, the left pinna
was treated with an equivalent volume of vehicle alone. Right and left
pinna thicknesses were measured at 1, 2, 4, 6, 8, 12, and 24 h after ICD
elicitation.
Central l-opioid receptor antagonism To assess the involvement of
central m-opioid receptors in morphine enhancement of the CHS
response in female and male rats, animals were stereotaxically implanted
with unilateral 22-gauge cannulae (Plastics One, Roanoke,VA) directed at
the left lateral ventricle before sensitization with DNFB on day 1 of the
experiment (Nelson and Lysle, 2001a). Sensitization and elicitation of
CHS were performed as described above. On the day before CHS
elicitation (day 5), animals received intracerebroventricular infusions of
20 mg of the irreversible m-opioid receptor b-funaltrexamine HCl
dissolved in 7.5 mL of 0.9% physiologic saline or saline alone. Twenty-
four hours after intracerebroventricular infusions, animals received
injections of either 15 mg per kg morphine or vehicle, and CHS was
elicited 1 h later. Pinna thickness was measured 24, 48, and 72 h after CHS
elicitation.
Measurement and data analysis Swelling was quanti¢ed by measuring
pinna thickness using a digimatic caliper (Mitutoyo, Kawasaki, Japan). At
each time point both the right (DNFB- or croton oil-treated) and the left
(control) pinnae were measured twice, and the means of each pinna
thickness were calculated for statistical analysis. If measurements di¡ered
by more than 0.05 mm, one additional measurement was taken and the
mean was calculated from the three measurements for use in the analyses.
This additional measurement was required in approximately 25% of all
cases throughout the experiments described herein. All measurements
were then compared to a baseline pinna thickness taken on the day before
elicitation of in£ammation to give a percentage of change from baseline
value. This metric was chosen as it allows standardization to control for
baseline di¡erences in ear thickness. The speci¢c formula used was
(measurement ^ baseline)/baseline100.
All data were analyzed using ANOVA. Where appropriate, standard
polynomial contrasts and Fisher’s LSD post hoc analyses were conducted to
probe main and interaction e¡ects (Kirk, 1982). Statistical signi¢cance for
all analyses was set at po0.05.
RESULTS
CHS response: vehicle treatment Pilot data indicated that the
concentration of DNFB used to elicit CHS on the pinna (0.5%)
produced no in£ammation in unsensitized male or female rats
(data not shown). Nevertheless, exposure to 0.5% DNFB in animals
sensitized with 1% DNFB produced pinna in£ammation under
drug-free conditions that reached a peak of 30% to 40% above
baseline at approximately 72 h after CHS elicitation and
declined thereafter toward baseline values (Fig 1). Consistent
with our hypotheses, there was no signi¢cant sex di¡erence in
the magnitude of the in£ammatory response following vehicle
treatment (Table I). Therefore, our experimental protocol
produced time-dependent in£ammation in control animals that
was speci¢c to sensitized animals and did not di¡er between
males and females.
Morphine: intact animals Morphine (F3,40¼ 25.76, po0.001,
Fig 1) signi¢cantly potentiated the in£ammatory e¡ects of
DNFB in a dose-dependent manner as evidenced by increased
pinna swelling for both males and females compared to vehicle
controls. There was also a signi¢cant e¡ect of sex (F1,40¼ 26.33,
po0.001), indicating that the pinnae of females swelled to a
signi¢cantly greater extent than those of males. Importantly, a
signi¢cant linear interaction between morphine and sex
(F1,40¼ 5.20, p¼ 0.028) was also observed, demonstrating that
the magnitude of the di¡erence between females and males
became greater with increasing doses of morphine. Supporting
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this ¢nding, post hoc analyses of the sex di¡erence at each dose
level revealed that, whereas pinna thickness in males and females
did not di¡er following vehicle administration, at each dose of
morphine tested females displayed signi¢cantly greater in£am-
mation than males (Table I). It is also interesting to note that
whereas treatment with 2.5 mg per kg morphine produced
signi¢cant enhancement of in£ammation in females compared
to saline (t(40)¼ 3.25, p¼ 0.02), this dose of morphine produced
no signi¢cant enhancement of in£ammation over saline
treatment in males (t(40)¼ 1.23, p¼ 0.23). Morphine did not
cause generalized cutaneous in£ammation independent of
DNFB treatment, because there was no signi¢cant treatment
e¡ect on the thickness of the vehicle-treated left ear
(F3,40¼ 0.252, p¼ 0.86). Therefore, morphine produces greater
peak in£ammatory e¡ects and is more potent in potentiating
DNFB-induced CHS in females than males.
To control for di¡erences in baseline ear thickness between
male and female animals, analyses were also performed using
raw di¡erence from baseline scores (i.e., pinna thickness ^
baseline thickness). Using this approach, the pattern of results
was similar to results obtained using percentage of change scores
(data not shown), indicating that sex di¡erences in response to
morphine treatment were independent of di¡erences in baseline
pinna thickness.
Etorphine: intact animals Etorphine signi¢cantly enhanced
pinna in£ammation in both female and male rats (F3,40¼39.66,
po0.001, Fig 2A), and females displayed signi¢cantly greater
in£ammation than males across all treatment conditions (F1,40¼
14.93, po0.001). Nevertheless, as with morphine treatment, a
signi¢cant linear interaction between etorphine treatment and
sex was observed (F1,40¼ 4.47, p¼ 0.041), indicating that the
magnitude of the sex di¡erence increased with greater doses of
etorphine. Post hoc comparisons revealed that females displayed
signi¢cantly greater in£ammation than males following
treatment with 0.01 and 0.005 mg per kg etorphine, but not
following vehicle or the 0.001 mg per kg dose (Table I).
Overall, the results obtained with etorphine are similar to those
obtained with morphine in that etorphine produced dose-
dependent enhancement of the CHS response in males and
females, and etorphine was signi¢cantly more potent in
producing proin£ammatory e¡ects in females than males.
Buprenorphine: intact animals The low-e⁄cacy m-opioid
buprenorphine signi¢cantly enhanced DNFB-induced pinna
swelling (F3,40¼11.13, po0.001, Fig 2B), and consistent with
other drugs tested, females displayed signi¢cantly greater
in£ammation than males (F1,40¼16.74, po0.001). The magnitude
of the sex di¡erence grew with increasing doses of
buprenorphine, as evidenced by a linear buprenorphine by sex
interaction (F1,40¼ 7.631, p¼ 0.009). Post hoc comparisons
indicated that a signi¢cant sex di¡erence was present following
treatment with 0.1 and 1.0 mg buprenorphine, but not following
vehicle or 0.01 mg per kg buprenorphine (Table I). These results
demonstrate that like the other m-opioids tested, buprenorphine
produced signi¢cantly greater enhancement of DNFB-induced
in£ammation in females than males.
Morphine: e¡ects on ICD To determine the speci¢city of sex
di¡erences in morphine potentiation of CHS, the e¡ect of 15 mg
per kg morphine given 1 h before application of 10% croton oil
was assessed. Morphine did not signi¢cantly alter the ICD
response (F1,19¼ 0.77, p¼ 0.39, Fig 3), nor was there a signi¢cant
sex di¡erence (F1,19¼ 0.344, p¼ 0.66) or morphine by sex inte-
raction (F1,19¼ 0.01, p¼ 0.92). Therefore, morphine’s sexually dimor-
phic enhancing e¡ects on CHS do not generalize to ICD, a
common immunologically nonspeci¢c form of cutaneous
in£ammation.
Central l-opioid receptor antagonism Following intracere-
broventricular pretreatment with 20 mg of the irreversible m-
opioid antagonist b-funaltrexamine, both male and female rats
displayed complete antagonism of morphine (15 mg/kg)
potentiation of CHS (F1,37¼ 29.08, po0.001, Fig 4). These data
demonstrate that morphine acts via m-opioid receptors in the
central nervous system and not those expressed on immunocytes
to enhance CHS in male and female rats. There was no sex dif-
ference in the magnitude of antagonism (F1,37¼0.60, p¼ 0.44),
indicating that activation of brain m-opioid receptors is
Figure1. Female Fischer rats display signi¢cantly
greater morphine-induced potentiation of the
CHS response than male rats. Pinna measurements
were taken from 12 to 192 h after CHS elicitation, and
data represent the percentage of change in pinna thick-
ness from a baseline value taken before DNFB applica-
tion (mean7SEM, n¼ 6). Whereas there was no
signi¢cant e¡ect of sex on the magnitude of in£amma-
tion following vehicle treatment (p¼ 0.256), females dis-
played increasingly greater in£ammation than males
with increasing doses of morphine (p¼ 0.028).
Table I. Post-Hoc Comparisons (Fisher’s LSD) of Sex
Di¡erences in the CHS Response FollowingVehicle or Opioid
Administration
Drug
Dose
(mg/kg)
Mean Di¡erence
(Females^Males) t df p
Vehicle (SterileWater) N/A 5.00 1.20 10 0.256
2.5 19.73 2.71 0.01
Morphine 7.5 20.33 2.80 40 0.008
15 29.49 4.06 0.001
0.001 6.57 0.75 0.457
Etorphine 0.05 17.53 2.63 40 0.012
0.01 22.30 3.35 0.002
0.01 5.31 0.76 0.449
Buprenorphine 0.1 14.30 2.18 40 0.035
1.0 28.97 4.42 0.001
SEX DIFFERENCES IN OPIOID MODULATION OF CHS 1055VOL. 121, NO. 5 NOVEMBER 2003
responsible for the e¡ects of morphine on CHS in both males
and females. Importantly, b-funaltrexamine had no e¡ect on the
CHS response following vehicle treatment (t(20)¼ 0.439,
p¼ 0.67), demonstrating that functional brain m-opioid receptors
are not required for the elicitation phase of CHS.
Gonadectomy experiment
Females In ovariectomized and sham-operated animals, there
was a signi¢cant e¡ect of both morphine treatment (F2,35¼
30.31, po0.001) and hormonal status (F1,35¼13.31, p¼ 0.001).
There was also a signi¢cant linear interaction between morphine
treatment and hormonal status (F1,35¼13.72, p¼ 0.001), indicating
that whereas there was no signi¢cant di¡erence in the magnitude
of in£ammation between ovariectomized and sham-operated
females following vehicle treatment, signi¢cant di¡erences
emerged following administration of increasing doses of mor-
phine (Fig 5A). These results indicate a crucial role of female go-
nadal hormones in potentiating morphine’s e¡ects on the CHS
response, but not the normal CHS response manifest in the
absence of drug treatment.
Males In this experiment, morphine treatment (F2,36¼ 65.40,
po0.001) enhanced the CHS response in castrated and sham-
operated males (Fig 5B). Additionally, there was a signi¢cant e¡ect
Figure 2. Female Fischer rats display signi¢cantly
greater (A) etorphine- and (B) buprenorphine-in-
duced potentiation of the CHS response than
male rats. Pinna measurements were taken from 12 to
192 h after CHS elicitation, and data represent the per-
centage of change in pinna thickness from a baseline
value taken before DNFB application (mean7SEM,
n¼ 6).Whereas no sex di¡erence was present following
vehicle treatment (p40.05), both etorphine (p¼ 0.041)
and buprenorphine (p¼ 0.009) produced concentration
dependently greater in£ammation in females than
males.
Figure 3. Morphine (15 mg/kg) does not alter the magnitude of
croton oil-induced ICD in female or male Fischer rats. Pinna mea-
surements were taken from 1 to 24 h after croton oil application, and data
represent the percentage of change in pinna thickness from a from a base-
line value taken prior to croton oil application (mean7SEM, n¼ 5^6).The
magnitude of in£ammation was una¡ected by morphine treatment
(p¼ 0.39) nor was there a signi¢cant sex di¡erence in the in£ammation
observed (p¼ 0.66).
Figure 4. Brain l-opioid receptors are responsible for morphine
potentiation of CHS in male and female rats. Animals received infu-
sions of the irreversible m-opioid antagonist b-funaltrexamine (20 mg) or
saline 24 h before treatment with vehicle or 15 mg per kg morphine (given
1 h before CHS elicitation). Data represent the percentage of change in pin-
na thickness from a baseline value taken the day before DNFB application
and are pooled from measurements taken at 24, 48, and 72 h after CHS
elicitation (mean7SEM, n¼ 5^7). b-Funaltrexamine treatment signi¢-
cantly antagonized morphine potentiation of the CHS response in males
and females (po0.001) but had no e¡ect on the magnitude of in£amma-
tion following vehicle treatment (p¼ 0.67).
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of hormonal status (F1,36¼17.07, po0.001) but not a morphine
by hormonal status interaction (F2,36¼1.12, p¼ 0.337). Therefore,
castration produced an increase in the magnitude of the CHS re-
sponse in males following both vehicle and morphine treatment.
This ¢nding suggests that the presence of male gonadal hor-
mones suppresses the CHS response. Nevertheless, the presence
of male gonadal hormones likely makes a limited contribution
to the sex di¡erences observed in gonadally intact animals
following morphine treatment, because hormone status and
morphine treatment do not interact to produce di¡erential in-
£ammatory responses in male animals.
DISCUSSION
This report demonstrates sex di¡erences in opioid modulation of
CHS and that gonadal hormones appear to play a critical role in
mediating this e¡ect. These experiments extend previous research
showing that morphine enhances the CHS response in male rats
(Nelson et al, 1999; Nelson and Lysle, 2001a) by demonstrating that
m-opioids with diverse pharmacologic properties produce signi¢-
cantly greater DNFB-induced cutaneous in£ammation in females
than males. By contrast, sex di¡erences are not present following
vehicle treatment, indicating that activation of the opioid system is
required for the emergence of sex di¡erences.The present data also
establish the potential of the clinically used analgesic buprenor-
phine and the high-e⁄cacy m-opioid etorphine to alter cutaneous
immune responses. In addition, these studies provide important
insights into the mechanisms underlying morphine’s potentiation
of CHS in that that morphine’s enhancement of the CHS response
in both male and female rats does not generalize to croton oil-in-
duced ICD and is mediated exclusively by activation of brain
m-opioid receptors. Finally, evidence that castration enhances
whereas ovariectomy suppresses morphine enhancement of CHS
suggests that the in£uence of gonadal hormone milieu is respon-
sible for the sex di¡erences observed in intact animals.
While it is clear that the magnitude of the CHS response is
signi¢cantly greater in females than males following treatment
with m-opioid agonists at the time of CHS elicitation, it remains
to be established which determinants of CHS are di¡erentially
altered in males and females in the presence of opioids. Previous
research in male rats demonstrated that mRNA levels of the
proin£ammatory mediators inducible nitric oxide synthase, inter-
leukin-6, and interferon-g were upregulated in the DNFB-
treated pinnae of morphine compared to saline-treated animals
at various time periods in the ¢rst 24 h after elicitation of CHS
(Nelson and Lysle, 2001b). In contrast, in the same investigations
there was no treatment-related change in the anti-in£ammatory
Th2-derived cytokine interleukin-10 over the same time course.
Therefore, it is possible that morphine preferentially potentiates
the expression in fermales of either proin£ammatory mediators
such as those described above or other cytokines known to be
involved in the expression of contact hypersensitivity such as in-
terleukin-1b or tumor necrosis factor-a (Kondo et al, 1995;
McHale et al, 1999). To address these possibilities, a time^course
examination of relevant monocyte and T lymphocyte-derived
cytokine levels in the pinna and their relation to sex and mor-
phine treatment is required.
In addition to cytokine expression, several other immunologic
and nonimmunologic mechanisms may prove to account for the
observed sex di¡erences. For instance, sex di¡erences may exist in
antigen processing or presentation, expression of cell adhesion
molecules (e.g., selectins), or anti-DNP antibody production
(Ray et al, 1983) following morphine treatment. Data from our
laboratory have also demonstrated that local pretreatment of the
pinna with the neurokinin-1 receptor antagonist WIN51,708 an-
tagonizes morphine potentiation of the CHS response in male
rats (Nelson and Lysle, 2001a). The endogenous neurokinin-1 li-
gand substance P appears to promote the induction of CHS (Nii-
zeki et al, 1999) and substance P agonists cause vasodilation and
plasma extravasation from cutaneous vasculature by releasing his-
tamine from cutaneous mast cells (Holzer, 1992). Therefore, sex
di¡erences in morphine enhancement of the CHS response may
be due to di¡erential modulation of the immunologic determi-
nants or vasoactive mediators involved in the induction of CHS.
The present experiments also provide evidence suggesting pu-
tative mechanisms underlying sex di¡erences in morphine en-
hancement of the CHS response. As evidenced by the failure of
morphine to promote croton oil-induced irritation of the pinna,
these data suggest that our ¢ndings do not generalize to other
Figure 5. Castration and ovariectomy produce opposing e¡ects on morphine enhancement of CHS. (A) Ovariectomy attenuates morphine po-
tentiation of CHS, as evidenced by a signi¢cant interaction between hormonal status and morphine treatment (p¼ 0.001). (B) Castration enhances CHS
following vehicle and morphine treatment, as evidenced by a signi¢cant e¡ect of castration (po0.001) and morphine treatment (po0.001), but no morphine
by castration interaction (p¼ 0.34). Pinna measurements were taken from 12 to 192 h after CHS elicitation, and data represent the percentage of change in
pinna thickness from a baseline measurement taken before DNFB application (mean7SEM, n¼ 5).
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forms of contact dermatitis. ICD accounts for 80% of cases of hu-
man contact dermatitis (Marks, 2002), does not require prior ex-
posure to the irritant, and is believed to result from release of
proin£ammatory cytokines from T lymphocytes and keratino-
cytes owing to acute tissue injury (Baadsgaard and Wang, 1991).
These data support previous research demonstrating that mor-
phine does not alter the course of ICD in male Lewis rats (Nel-
son et al, 1999) and suggest that the greater enhancement of CHS
in females by morphine occurs via interaction with antigen-spe-
ci¢c e¡ector mechanisms. Another important ¢nding concerning
mechanisms of morphine potentiation of CHS is that these
e¡ects occur owing to activation of brain m-opioid receptors.
Because morphine has been shown to alter immune responses
via interaction with opioid receptors located in the brain (Mellon
and Bayer, 1998) and those expressed on immunocytes (Eisenstein
and Hilburger, 1998), it was of critical importance to determine
the anatomic distribution and speci¢c subtype of opioid receptor
responsible for these e¡ects. Therefore, future studies will focus
on potential sex di¡erences in central m-opioid function that
might account for sex di¡erences in morphine’s e¡ects on CHS.
Our results demonstrate that ovariectomized females treated
with morphine, but not vehicle, display attenuated CHS re-
sponses compared to intact females. In contrast, castration signif-
icantly enhances both the basal and the morphine-modulated
CHS response in males. Together, these ¢ndings suggest that
males and females have unique hormonal milieus that contribute
di¡erentially to the expression of CHS following morphine or
vehicle treatment. Nevertheless, unlike the enhancing e¡ect of
castration in male animals which was relatively equivalent follow-
ing both vehicle and morphine treatment, the dramatic inhibi-
tory e¡ect of ovariectomy on the CHS response is only apparent
following morphine treatment. Therefore, the presence of female
gonadal hormones is likely largely responsible for the sex di¡er-
ences in opioid-potentiated in£ammation in intact animals. This
pattern of opposing e¡ects of female and male gonadal hormones
on immune parameters (Leposavic et al, 1996;Travi et al, 2002) and
responses to opioids (Terner et al, 2002) has been well established
in other investigations. Nevertheless, the unique feature of the
current investigations is that the e¡ects of gonadectomy, and in
particular ovariectomy, on CHS emerged in the presence of mor-
phine treatment. Although the goal of the present studies was not
to determine the hormonal locus of these e¡ects, gonadectomy
produces a marked suppression of circulating prolactin levels
(Shaar et al, 1975), an anterior pituitary hormone whose plasma
levels are increased by morphine (Baumann et al, 2000). Because
prolactin produces proin£ammatory e¡ects by promoting a Th1
cytokine pro¢le, it will be important to consider the potential
role of this hormone in sex di¡erence in morphine modulation
of CHS (Whitacre et al, 1999; McMurray, 2001).
A ¢nal key feature of these investigations is that the increased
sensitivity to morphine observed in females generalized to other
m-opioid drugs with varying pharmacologic properties. For in-
stance, whereas morphine and etorphine are both highly selective
m-opioid agonists (Aceto et al, 1997; Emmerson et al, 1994), bupre-
norphine also displays activity as an antagonist at k and d recep-
tors (Negus and Dykstra, 1988; Tzschentke, 2002). Furthermore,
buprenorphine is classi¢ed as a low-e⁄cacy agonist at the
m-opioid receptor (Tzschentke, 2002), because it antagonizes the
action of higher-e⁄cacy opioid agonists such as morphine or
etorphine. Morphine, etorphine, and buprenorphine also have
di¡erent half-lives in plasma, with an order of buprenorphine
4morphine4etorphine (Aceto et al, 1997; Gades et al, 2000).
These di¡erences in selectivity, e⁄cacy, and pharmacokinetics de-
monstrate that sex di¡erences in opioid modulation of the CHS
response are generalizable across a range of m-opioids and are not
speci¢c to the unique pharmacologic properties of one m-opioid
drug. Nevertheless, such pharmacologic di¡erences may account
for the discrepancy in time course and magnitude of CHS en-
hancement following treatment with morphine, etorphine, and
buprenorphine (see Figs 1, 2).
The present ¢ndings represent a signi¢cant contribution to the
literature concerning sex di¡erences in cutaneous immune re-
sponses and pharmacologic modulation of the CHS response.
Our studies demonstrate that although there are no signi¢cant
sex di¡erences in the CHS response following vehicle treatment,
there are profound di¡erences in sensitivity to opioids with fe-
males demonstrating signi¢cantly potentiated in£ammation
compared to males across a broad range of doses of morphine,
buprenorphine, and etorphine. These e¡ects appear speci¢c to
DNFB-induced CHS because morphine has no e¡ect on croton
oil-induced in£ammation. Furthermore, morphine enhancement
of CHS depends on the activation of brain m-opioid receptors
and on gonadal hormone milieu. Similar sex di¡erences have
been reported in both morphine’s physiologic e¡ects (Sarton
et al, 1999; Sarton et al, 2000; Zun et al, 2002) and the magnitude
of the CHS response (Rees et al, 1989) in humans. Given the ap-
parently similar dynamic in morphine sensitivity between hu-
mans and our rat model, these data suggest the likelihood that
morphine may exacerbate cutaneous allergic responses to a great-
er extent in women than men. Because CHS is widely studied as
a prototype delayed-type hypersensitivity response, it is possible
that opioids may produce sexually dimorphic modulation of a
range of delayed-type hypersensitivity-dependent immune re-
sponses, including host defense and autoimmune susceptibility.
Overall, these data suggest the need to consider sex as a determi-
nant of opioid-induced immunomodulation.
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